Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Lineage Cell Therapeutics
(AMEX:LCTX)
Intraday
$1.17
0.03
[2.63%]
After-Hours
$1.17
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$1.17
0.03
[2.63%]
At close: Apr 23
$1.17
0
[0.00%]
After Hours: 9:26AM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Lineage Cell Therapeutics Stock (AMEX:LCTX)
Lineage Cell Therapeutics Stock (AMEX: LCTX)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, March 22, 2024
Lineage Cell Therapeutics Inc May Offer And Sell Common Shares Of Up To $40M From Time To Time Through Or To B. Riley
Benzinga Newsdesk
-
Mar 22, 2024, 4:36PM
Lineage Cell Therapeutics Entered Into Sales Agreement With B. Riley Securities; Effective As Of March 18 Controlled Equity Offering Sales Agreement Between Co And Cantor Fitzgerald & Co. Was Terminated; On March 12 Received Written Correspondence From U.S. FDA Regarding Its Ind As Amended For OPC1; Per Correspondence, FDA Advised That Company Not Initiate Proposed Clinical Study Until It Has Received FDA Feedback; FDA Anticipates Providing Feedback By April 26, 2024
Benzinga Newsdesk
-
Mar 22, 2024, 4:29PM
Wednesday, March 13, 2024
Lineage Cell Therapeutics, Inc. Announces RG6501 (OpRegen) Phase 1/2a Clinical Study 24 Month Results To Be Featured At 2024 Retinal Cell & Gene Therapy Innovation Summit
Happy Mohamed
-
Mar 13, 2024, 8:13AM
Monday, March 11, 2024
Lineage Cell Therapeutics Announces OpRegen Preclinical Engraftment Results To Be Presented At 2024 Association For Research In Vision And Ophthalmology Meeting
Benzinga Newsdesk
-
Mar 11, 2024, 8:06AM
Friday, March 08, 2024
HC Wainwright & Co. Reiterates Buy on Lineage Cell Therapeutics, Maintains $7 Price Target
Benzinga Newsdesk
-
Mar 8, 2024, 6:12AM
Thursday, March 07, 2024
Lineage Cell Therapeutics: Q4 Earnings Insights
Benzinga Insights
-
Mar 7, 2024, 4:05PM
Lineage Cell Therapeutics Q4 2023 GAAP EPS $(0.030) Beats $(0.040) Estimate, Sales $2.100M Beat $1.310M Estimate
Benzinga Newsdesk
-
Mar 7, 2024, 4:02PM
Earnings Scheduled For March 7, 2024
Benzinga Insights
-
Mar 7, 2024, 4:49AM
Wednesday, March 06, 2024
A Preview Of Lineage Cell Therapeutics's Earnings
Benzinga Insights
-
Mar 6, 2024, 1:02PM
Wednesday, February 14, 2024
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights
-
Feb 14, 2024, 8:05AM
Tuesday, February 13, 2024
HC Wainwright & Co. Reiterates Buy on Lineage Cell Therapeutics, Maintains $7 Price Target
Benzinga Newsdesk
-
Feb 13, 2024, 12:38PM
Lineage Announces FDA Clearance Of IND Amendment For OPC1 Cell Transplant For The Treatment Of Spinal Cord Injury
Benzinga Newsdesk
-
Feb 13, 2024, 8:06AM
Tuesday, February 06, 2024
Lineage Cell Therapeutics Announces $14M Million Registered Direct Offering
Benzinga Newsdesk
-
Feb 6, 2024, 9:17AM
Monday, February 05, 2024
Cantor Fitzgerald Reiterates Overweight on Lineage Cell Therapeutics, Maintains $6 Price Target
Benzinga Newsdesk
-
Feb 5, 2024, 9:27AM
Thursday, February 01, 2024
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights
-
Feb 1, 2024, 4:31PM
Tuesday, January 16, 2024
Lineage Cell Therapeutics, Inc. Announces RG6501 Phase 1/2a Results Will Be Featured At 2024 Angiogenesis Exudation And Degeneration Meeting In Presentation By Allen Ho, MD, FACS, FASRS
Benzinga Newsdesk
-
Jan 16, 2024, 8:23AM
Wednesday, January 03, 2024
Lineage Cell Therapeutics, Longeveron And 2 Other Stocks Under $2 Insiders Are Buying
Avi Kapoor
-
Jan 3, 2024, 7:11AM
Friday, December 29, 2023
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights
-
Dec 29, 2023, 8:05AM
Monday, December 18, 2023
Lineage Cell Therapeutics, Inc. Submits Investigational New Drug Amendment To FDA For OPC1 For Treatment Of Chronic And Subacute Spinal Cord Injury
Benzinga Newsdesk
-
Dec 18, 2023, 8:09AM
Thursday, November 09, 2023
Lineage Cell Therapeutics: Q3 Earnings Insights
Benzinga Insights
-
Nov 9, 2023, 4:35PM
Lineage Cell Therapeutics Q3 EPS $(0.04), Inline, Sales $1.25M Miss $2.59M Estimate
Benzinga Newsdesk
-
Nov 9, 2023, 4:31PM
Earnings Scheduled For November 9, 2023
Benzinga Insights
-
Nov 9, 2023, 6:52AM
Wednesday, November 08, 2023
Earnings Preview: Lineage Cell Therapeutics
Benzinga Insights
-
Nov 8, 2023, 11:01AM
Tuesday, October 24, 2023
RG6501 Phase 1/2a Results To Be Featured At Eyecelerator At 2023 American Academy Of Ophthalmology Annual Meeting
Benzinga Newsdesk
-
Oct 24, 2023, 8:16AM
Wednesday, October 11, 2023
Lineage Announces Issuance Of U.S. Patent Covering Proprietary Manufacturing And Differentiation Process For Retinal Pigmented Epithelial Cells
Benzinga Newsdesk
-
Oct 11, 2023, 8:01AM
Thursday, October 05, 2023
Lineage Cell Therapeutics' RG6501 (OpRegen) Phase 1/2a Results Show Evidence of Rapid Improvement of Outer Retinal Structure in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Benzinga Newsdesk
-
Oct 5, 2023, 8:02AM
Wednesday, September 13, 2023
Lineage Cell Therapeutics Announces RG6501 Phase 1/2A Additional Results to Be Featured At 23rd EURETINA Congress
Benzinga Newsdesk
-
Sep 13, 2023, 8:19AM
Wednesday, September 06, 2023
EXCLUSIVE: Cell Therapy Player Lineage Cell Therapeutics Starts Development Activities Under Licensing Pact With Eterna Therapeutics
Vandana Singh
-
Sep 6, 2023, 7:40AM
EXCLUSIVE: Lineage Cell Therapeutics Tells Benzinga It Has Development Activities For Hypoimmune Pluripotent Cell Line For Neurology Indications Under Co.'s Partnership With Eterna Therapeutics
Benzinga Newsdesk
-
Sep 6, 2023, 7:40AM
Wednesday, August 16, 2023
Why DLocal Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket
Lisa Levin
-
Aug 16, 2023, 8:19AM
Friday, August 11, 2023
HC Wainwright & Co. Reiterates Buy on Lineage Cell Therapeutics, Maintains $7 Price Target
Benzinga Newsdesk
-
Aug 11, 2023, 6:25AM
Thursday, August 10, 2023
Lineage Cell Therapeutics Q2 EPS $(0.03) Beats $(0.04) Estimate, Sales $3.23M Beat $2.20M Estimate
Benzinga Newsdesk
-
Aug 10, 2023, 4:09PM
Earnings Scheduled For August 10, 2023
Benzinga Insights
-
Aug 10, 2023, 6:59AM
Wednesday, August 09, 2023
Lineage Cell Therapeutics Earnings Preview
Benzinga Insights
-
Aug 9, 2023, 1:02PM
Tuesday, July 25, 2023
Cantor Fitzgerald Reiterates Overweight on Lineage Cell Therapeutics, Maintains $6 Price Target
Benzinga Newsdesk
-
Jul 25, 2023, 7:56AM
Monday, July 24, 2023
Lineage Cell Therapeutics' Lung Cancer Vaccine: Initial Data Reveals Modest, Durable Immune Response
Vandana Singh
-
Jul 24, 2023, 1:12PM
HC Wainwright & Co. Reiterates Buy on Lineage Cell Therapeutics, Maintains $7 Price Target
Benzinga Newsdesk
-
Jul 24, 2023, 12:54PM
Lineage Cell Therapeutics, Cancer Research UK Report Topline Phase 1 Study Results With VAC2 For Advanced Non-small Cell Lung Cancer
Benzinga Newsdesk
-
Jul 24, 2023, 8:10AM
Tuesday, July 04, 2023
Lineage Cell Therapeutics Board Member Awarded $70K Worth of Stock Options
Benzinga Insights
-
Jul 4, 2023, 11:01AM
Lineage Cell Therapeutics Director Awarded $70K Worth of Stock Options
Benzinga Insights
-
Jul 4, 2023, 11:01AM
Lineage Cell Therapeutics Chairman Awarded $70K Worth of Stock Options
Benzinga Insights
-
Jul 4, 2023, 11:01AM
Director at Lineage Cell Therapeutics Acquires Company Stock Options Worth 50,000 Shares
Benzinga Insights
-
Jul 4, 2023, 11:01AM
Board Member at Lineage Cell Therapeutics Acquires Company Stock Options Worth 50,000 Shares
Benzinga Insights
-
Jul 4, 2023, 11:01AM
Friday, May 12, 2023
HC Wainwright & Co. Reiterates Buy on Lineage Cell Therapeutics, Maintains $7 Price Target
Benzinga Newsdesk
-
May 12, 2023, 6:34AM
Thursday, May 11, 2023
Lineage Cell Therapeutics: Q1 Earnings Insights
Benzinga Insights
-
May 11, 2023, 5:34PM
Lineage Cell Therapeutics Q1 EPS $(0.03) Vs. $(0.04) Prior Year, Sales $2.39M Beat $2.01M Estimate
Benzinga Newsdesk
-
May 11, 2023, 4:12PM
Earnings Scheduled For May 11, 2023
Benzinga Insights
-
May 11, 2023, 9:58AM
Wednesday, April 26, 2023
Lineage Cell Therapeutics, Inc. Highlights Presentation Of RG6501 Phase 1/2a Data At ARVO 2023
Benzinga Newsdesk
-
Apr 26, 2023, 8:19AM
HC Wainwright & Co. Reiterates Buy on Lineage Cell Therapeutics, Maintains $7 Price Target
Benzinga Newsdesk
-
Apr 26, 2023, 6:12AM
Thursday, April 13, 2023
Harley-Davidson, Sportsman's Warehouse And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Lisa Levin
-
Apr 13, 2023, 6:41AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch